Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer

2020419 citationsJournal Articlebronze Open Access

Authors

Neal D. Shore · Carolina Urologic Research Center

Fred Saad · Université de Montréal

Michael S. Cookson · University of Oklahoma Health Sciences Center

Daniel J. George · Duke University

Daniel R. Saltzstein · Urology San Antonio

Ronald Tutrone · Chesapeake Urology Associates

Hideyuki Akaza

Abstract

In this trial involving men with advanced prostate cancer, relugolix achieved rapid, sustained suppression of testosterone levels that was superior to that with leuprolide, with a 54% lower risk of major adverse cardiovascular events. (Funded by Myovant Sciences; HERO ClinicalTrials.gov number, NCT03085095.).

Topics & Keywords

Prostate Cancer Treatment and Research Hormonal and reproductive studies Estrogen and related hormone effects

Publication Details

Published in: New England Journal of Medicine

Volume 382, Issue 23, pp. 2187-2196

DOI: 10.1056/nejmoa2004325

Field-Weighted Citation Impact: 34.10

Command Palette

Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer

Authors

Abstract

Topics & Keywords

Publication Details